Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | LTA4H | P09960 | 4/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302462 | 0.88 | LMNA (0.70) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5660490 | 0.86 | ALDH1A1 (0.73) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL3301180 | 0.86 | LMNA (0.68) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5660969 | 0.85 | ALDH1A1 (0.64) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5314942 | 0.84 | LTA4H (0.73) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5661423 | 0.84 | LMNA (0.64) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5660090 | 0.83 | ALDH1A1 (0.68) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5663066 | 0.83 | LMNA (1.00) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5661692 | 0.82 | ALDH1A1 (0.74) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5334244 | 0.82 | ALDH1A1 (0.97) | LMNAGAASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LMNA 1402/4885GAA 1586/4885SMN1; SMN2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.